Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review

References

• Soeters PB, Schols AM: Advances in understanding and assessing malnutrition. Curr Opin Clin Nutr Metab Care 12, 487–494, 2009. doi: 10.1097/MCO.0b013e32832da243
   PubMed Web of Science ®Google Scholar
• Nicolini A, Ferrari P, Masoni MC, Fini M, Pagani S, et al.: Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. Biomed Pharmacother 67, 807–817, 2013. doi: 10.1016/j.biopha.2013.08.005.S0753-3322(13)00094-2[pii]
   PubMed Web of Science ®Google Scholar
• Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ: Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res 2, 27–38, 2010.
   PubMedGoogle Scholar
• Paci A, Veal G, Bardin C, Leveque D, Widmer N, et al.: Review of therapeutic drug monitoring of anticancer drugs part 1-cytotoxics. Eur J Cancer 50, 2010–2019, 2014. doi: 10.1016/j.ejca.2014.04.014.S0959-8049(14)00599-1[pii]
   PubMed Web of Science ®Google Scholar
• Bozzetti F: Why the oncologist should consider the nutritional status of the elderly cancer patient. Nutrition 31, 590–593, 2015. doi: 10.1016/j.nut.2014.12.005.S0899-9007(14)00505-X[pii]
   PubMed Web of Science ®Google Scholar
• Murry DJ, Riva L, Poplack DG: Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 11, 48–51, 1998.
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3, 330–338, 2003. doi: 10.1038/nrc1074.nrc1074[pii]
   PubMed Web of Science ®Google Scholar
• Grem JL: 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18, 299–313, 2000.
   PubMed Web of Science ®Google Scholar
• Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7, 288–323, 2002.
   PubMed Web of Science ®Google Scholar
• Torosian MH, Jalali S, Nguyen HQ: Protein intake and 5-fluorouracil toxicity in tumor-bearing animals. J Surg Res 49, 298–301, 1990.
   PubMed Web of Science ®Google Scholar
• Davis LE, Lenkinski RE, Shinkwin MA, Kressel HY, Daly JM: The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Cancer 72, 3715–3722, 1993.
   PubMed Web of Science ®Google Scholar
• Borelli P, Barros FE, Nakajima K, Blatt SL, Beutler B, et al.: Protein-energy malnutrition halts hemopoietic progenitor cells in the G0/G1 cell cycle stage, thereby altering cell production rates. Braz J Med Biol Res 42, 523–530, 2009. doi: S0100-879X2009000600008 [pii].
   PubMed Web of Science ®Google Scholar
• Motawi TK, Abd-Elgawad HM, Shahin NN: Effect of protein malnutrition on the metabolism and toxicity of cisplatin, 5-fluorouracil and mitomycin C in rat stomach. Food Chem Toxicol 56, 467–482, 2013. doi: 10.1016/j.fct.2013.02.042.S0278-6915(13)00151-8[pii]
   PubMed Web of Science ®Google Scholar
• Fleming RA, Milano GA, Etienne MC, Renee N, Thyss A, et al.: No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. Br J Cancer 66, 668–672, 1992.
   PubMed Web of Science ®Google Scholar
• Young AM, Kidston S, Banks MD, Mudge AM, Isenring EA: Malnutrition screening tools: comparison against two validated nutrition assessment methods in older medical inpatients. Nutrition 29, 101–106, 2013. doi: 10.1016/j.nut.2012.04.007.S0899-9007(12)00174-8[pii]
   PubMed Web of Science ®Google Scholar
• Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R: Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 54, 131–139, 2002. doi: 1598 [pii].
   PubMed Web of Science ®Google Scholar
• Hasenberg T, Essenbreis M, Herold A, Post S, Shang E: Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomized clinical trial. Colorectal Dis 12, e190–e199, 2010. doi: 10.1111/j.1463-1318.2009.02111.x.CDI2111[pii]
   Google Scholar
• Chabner BA, Allegra CJ: Antifolates. In: Cancer Chemotherapy and Biotherapy: Principles and Practice (5e ed.). Lippincott Williams & Wilkins: Philadelphia, 2011.
   Google Scholar
• Schmiegelow K: Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146, 489–503, 2009. doi: 10.1111/j.1365-2141.2009.07765.x.BJH7765[pii]
   PubMed Web of Science ®Google Scholar
• Charland SL, Bartlett D, Torosian MH: Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. JPEN J Parenter Enteral Nutr 18, 45–49, 1994.
   PubMed Web of Science ®Google Scholar
• Dunki Jacobs PB, Ruevekamp M, Varossiau FJ, Hart GA, de Graaf PW: Alterations in serum levels, anti-tumor activity and toxicity of methotrexate in rats after a short period of nutritional depletion. Eur J Cancer Clin Oncol 25, 415–422, 1989.
   PubMedGoogle Scholar
• Grossie VB, Jr., Loo TL: Effect of nutritional status on the hepatobiliary excretion of methotrexate in the rat. Cancer Treat Rep 67, 253–257, 1983.
   PubMedGoogle Scholar
• Mihranian MH, Wang YM, Daly JM: Effects of nutritional depletion and repletion on plasma methotrexate pharmacokinetics. Cancer 54, 2268–2271, 1984.
   PubMed Web of Science ®Google Scholar
• Torosian M: Effect of protein-intake on dihydrofolate-reductase activity of host and tumor-tissues. Int J Oncol 5, 1119–1123, 1994.
   PubMed Web of Science ®Google Scholar
• Grossie VB, Jr., Ho DH, Loo TL: Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat. Cancer Treat Rep 66, 85–89, 1982.
   PubMedGoogle Scholar
• Torosian MH, Mullen JL, Miller EE, Zinnser KR, Buzby GP: Reduction of methotrexate toxicity with improved nutritional status in tumor-bearing animals. Cancer 61, 1731–1735, 1988.
   PubMed Web of Science ®Google Scholar
• Daly JM, Reynolds HM, Rowlands BJ, Dudrick SJ, Copeland EM, 3rd: Tumor growth in experimental animals: nutritional manipulation and chemotherapeutic response in the rat. Ann Surg 191, 316–322, 1980.
   PubMed Web of Science ®Google Scholar
• Reynolds HM, Jr., Daly JM, Rowlands BJ, Dudrick SJ, Copeland EM, 3rd: Effects of nutritional repletion on host and tumor response to chemotherapy. Cancer 45, 3069–3074, 1980.
   PubMed Web of Science ®Google Scholar
• Kumar RV, Gokhale SV, Ambaye RY, Shetty PA: Pharmacokinetics of methotrexate in Indian children and its relationship to nutritional status. Chemotherapy 33, 234–239, 1987.
   PubMed Web of Science ®Google Scholar
• Rajeswari R, Shetty PA, Gothoskar BP, Akolkar PN, Gokhale SV: Pharmacokinetics of methotrexate in adult Indian patients and its relationship to nutritional status. Cancer Treat Rep 68, 727–732, 1984.
   PubMedGoogle Scholar
• Lobato-Mendizabal E, Ruiz-Arguelles GJ, Marin-Lopez A: Leukaemia and nutrition. I: Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. Leuk Res 13, 899–906, 1989.
   PubMed Web of Science ®Google Scholar
• Israels T, van de Wetering MD, Hesseling P, van Geloven N, Caron HN, et al.: Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi. Pediatr Blood Cancer 53, 47–52, 2009. doi: 10.1002/pbc.22032
   PubMed Web of Science ®Google Scholar
• Chabner BA, Allegra CJ: Topoisomerase II Inhibitors: Anthracyclines. In: Cancer Chemotherapy and Biotherapy: Principles and Practice (5e ed.). Lippincott Williams & Wilkins: Philadelphia, 2011.
   Google Scholar
• Kapelanski DP, Daly JM, Copeland EM, 3rd, Dudrick SJ: Doxorubicin pharmacokinetics – the effects of protein deprivation. J Surg Res 30, 331–337, 1981. doi: 0022-4804(81)90167-0 [pii].
   PubMed Web of Science ®Google Scholar
• Cusack BJ, Young SP, Loseke VL, Hurty MR, Beals L, et al.: Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 30, 145–148, 1992.
   PubMed Web of Science ®Google Scholar
• Kim YG, Cho MK, Kwon JW, Kim SG, Lee MG: Effects of cysteine on the pharmacokinetics of intravenous adriamycin in rats with protein-calorie malnutrition. Res Commun Mol Pathol Pharmacol 107, 361–376, 2000.
   PubMed Web of Science ®Google Scholar
• El-Demerdash E, Ali AA, El-Taher DE, Hamada FM: Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity. J Pharm Pharmacol 64, 344–352, 2012. doi: 10.1111/j.2042-7158.2011.01413.x
   PubMed Web of Science ®Google Scholar
• Crescimanno M, Flandina C, Rausa L, Sanguedolce R, D'Alessandro N: Morphological changes and catalase activity in the hearts of CD 1 mice following acute starvation or single doses of doxorubicin, epirubicin or mitoxantrone. Chemioterapia 7, 53–59, 1988.
   PubMedGoogle Scholar
• Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, et al.: An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67, 93–101, 2011. doi: 10.1007/s00280-010-1288-y
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73, 994–1007, 2008. doi: 10.1038/sj.ki.5002786.5002786[pii]
   PubMed Web of Science ®Google Scholar
• Skinner R: Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 40, 2352–2354, 2004. doi: S0959-8049(04)00615-X [pii]. 10.1016/j.ejca.2004.08.002
   PubMed Web of Science ®Google Scholar
• Lautermann J, Schacht J: [Reduced nutritional status enhances ototoxicity]. Laryngorhinootologie 74, 724–727, 1995. doi: 10.1055/s-2007-997833
   PubMed Web of Science ®Google Scholar
• Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, Serna-Thome MG, Flores-Estrada D, et al.: Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10, 50, 2010. doi: 10.1186/1471-2407-10-50.1471-2407-10-50[pii]
   PubMed Web of Science ®Google Scholar
• Chatterjee D, Roy S, Hazra A, Dasgupta P, Ganguly S, et al.: Variation of adverse drug reaction profile of platinum-based chemotherapy with body mass index in patients with solid tumors: an observational study. Indian J Pharmacol 46, 222–224, 2014. doi: 10.4103/0253-7613.129325.IJPharm-46-222[pii]
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, et al.: Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 102, 2557–2563, 2007. doi: AJG1437 [pii]. 10.1111/j.1572-0241.2007.01437.x
   PubMed Web of Science ®Google Scholar
• McRackan TR, Watkins JM, Herrin AE, Garrett-Mayer EM, Sharma AK, et al.: Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope 118, 1180–1185, 2008. doi: 10.1097/MLG.0b013e31816fca5c
   PubMed Web of Science ®Google Scholar
• Israels T, Damen CW, Cole M, van Geloven N, Boddy AV, et al.: Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. Eur J Cancer 46, 1841–1847, 2010. doi: 10.1016/j.ejca.2010.03.002.S0959-8049(10)00192-9[pii]
   PubMed Web of Science ®Google Scholar
• Gomber S, Dewan P, Chhonker D: Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 77, 97–100, 2010. doi: 10.1007/s12098-009-0254-3
   PubMed Web of Science ®Google Scholar
• Kumar N: Nutritional neuropathies. Neurol Clin 25, 209–255, 2007. doi: S0733-8619(06)00106-X [pii]. 10.1016/j.ncl.2006.11.001
   PubMed Web of Science ®Google Scholar
• Weber GA, Sloan P, Davies D: Nutritionally induced peripheral neuropathies. Clin Podiatr Med Surg 7, 107–128, 1990.
   PubMedGoogle Scholar
• Clark PI, Slevin ML: The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12, 223–252, 1987. doi: 10.2165/00003088-198712040-00001
   PubMed Web of Science ®Google Scholar
• Suh JH, Kang HE, Yoon IS, Yang SH, Kim SH, et al.: Cysteine effects on the pharmacokinetics of etoposide in protein-calorie malnutrition rats: increased gastrointestinal absorption by cysteine. Xenobiotica 41, 885–894, 2011. doi: 10.3109/00498254.2011.585186
   PubMed Web of Science ®Google Scholar
• Spronck JC, Nickerson JL, Kirkland JB: Niacin deficiency alters p53 expression and impairs etoposide-induced cell cycle arrest and apoptosis in rat bone marrow cells. Nutr Cancer 57, 88–99, 2007. doi: 10.1080/01635580701268337
   PubMed Web of Science ®Google Scholar
• Stuurman FE, Nuijen B, Beijnen JH, Schellens JH: Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet 52, 399–414, 2013. doi: 10.1007/s40262-013-0040-2
   PubMed Web of Science ®Google Scholar
• Perez-Pitarch A, Nacher A, Merino V, Catalan-Latorre A, Jimenez-Torres NV, et al.: Impact of nutritional status on the pharmacokinetics of erlotinib in rats. Biopharm Drug Dispos, 2015. doi: 10.1002/bdd.1948
   PubMed Web of Science ®Google Scholar
• McMurray DN, Bartow RA, Mintzer CL: Protein malnutrition alters the distribution of Fc gamma R+ (T gamma) and Fc mu R+ (T mu) T lymphocytes in experimental pulmonary tuberculosis. Infect Immun 58, 563–565, 1990.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, et al.: Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 30, 777–789, 2010. doi: 10.1007/s10875-010-9468-4
   PubMed Web of Science ®Google Scholar
• Park S, Han B, Cho JW, Woo SY, Kim S, et al.: Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer 66, 225–233, 2014. doi: 10.1080/01635581.2014.867065
   PubMed Web of Science ®Google Scholar
• Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, et al.: PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 21, 237–242, 2011. doi: 10.1097/FPC.0b013e32833c6107
   PubMed Web of Science ®Google Scholar
• Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, et al.: PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 21, 679–686, 2011. doi: 10.1097/FPC.0b013e328343dd93
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, et al.: Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21, 440–446, 2011. doi: 10.1097/FPC.0b013e32833ffb56
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, et al.: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92, 414–417, 2012. doi: 10.1038/clpt.2012.96.clpt201296[pii]
   PubMed Web of Science ®Google Scholar
• Yang J, Bogni A, Schuetz EG, Ratain M, Dolan ME, et al.: Etoposide pathway. Pharmacogenet Genomics 19, 552–553, 2009. doi: 10.1097/FPC.0b013e32832e0e7f
   PubMed Web of Science ®Google Scholar
• Lagas JS, Fan L, Wagenaar E, Vlaming ML, van Tellingen O, et al.: P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 16, 130–140, 2010. doi: 10.1158/1078-0432.CCR-09-1321.1078-0432.CCR-09-1321[pii]
   PubMed Web of Science ®Google Scholar
• Terada T, Noda S, Inui K: Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 152, 125–134, 2015. doi: 10.1016/j.pharmthera.2015.05.009.S0163-7258(15)00100-X[pii]
   PubMed Web of Science ®Google Scholar